Disease-Modifying Therapy

Five-Year Ublituximab Treatment Shows Sustained Benefits in Relapsing Multiple Sclerosis: ULTIMATE Extension Study

Long-term data from the ULTIMATE open-label extension study demonstrates sustained efficacy and safety of ublituximab in relapsing multiple sclerosis over five years, with significant reductions in relapse rates and disability progression c